Michael J. Campbell, PhD

A B C D E F G H I J K L M N O P Q R S T U V W X Y Z
Michael J. Campbell, PhD

Assistant Adjunct Professor, Department of Surgery, UCSF

campbellm@surgery.ucsf.edu

Phone: (415) 885-3710 (voice)
Box 1674, UCSF
San Francisco, CA 94143-1674

View on UCSF Profiles

Cancer Center Membership

Associate Member » Breast Oncology» Cancer, Immunity, and Microenvironment

Education

University of Puget Sound, Tacoma, WA, B.S., 1978-1982, Biology
Stanford University, Stanford, CA, Ph.D., 1982-1987, Cancer Biology
Stanford University, Stanford, CA, post-doc, 1987-1989, Tumor immunology and immunotherapy


Professional Experience

  • 1989-1991
    Research Associate, Department of Medicine/Division of Oncology, Stanford University, School of Medicine, Stanford, CA.
  • 1991-1992
    Research Associate, Department of Surgery, Stanford University School of Medicine, Stanford, CA.
  • 1992-1997
    Research Assistant Professor, Department of Surgery, Stanford University School of Medicine, Stanford, CA.
  • 1997-present
    Assistant Adjunct Professor, Department of Surgery, University of California, San Francisco, CA

Honors & Awards

  • 1982-1986
    NIH - National Research Service Award, Graduate Fellowship
  • 1987-1988
    Stanford University Dean's Postdoctoral Fellowship Award
  • 1988-1989
    NIH - National Research Service Award, Postdoctoral Fellowship

Selected Publications

  1. Survival from Differentiated Thyroid Cancer: What Has Age Got to Do with It? Thyroid. 2015 Oct; 25(10):1106-14.
    View on PubMed
  2. The underestimated risk of cancer in patients with multinodular goiters after a benign fine needle aspiration. World J Surg. 2015 Mar; 39(3):695-700.
    View on PubMed
  3. Two-phase (low-dose) computed tomography is as effective as 4D-CT for identifying enlarged parathyroid glands. Int J Surg. 2015 Feb; 14:80-4.
    View on PubMed
  4. Unanticipated thyroid cancer in patients with substernal goiters: are we underestimating the risk? Ann Surg Oncol. 2015 Apr; 22(4):1214-8.
    View on PubMed
  5. Immune evasion mediated by tumor-derived lactate dehydrogenase induction of NKG2D ligands on myeloid cells in glioblastoma patients. Proc Natl Acad Sci U S A. 2014 Sep 2; 111(35):12823-8.
    View on PubMed
  6. Adrenalectomy outcomes are superior with the participation of residents and fellows. J Am Coll Surg. 2014 Jul; 219(1):53-60.
    View on PubMed
  7. Prognostic value of cardiovascular magnetic resonance imaging measurements corrected for age and sex in idiopathic pulmonary arterial hypertension. Circ Cardiovasc Imaging. 2014 Jan; 7(1):100-6.
    View on PubMed
  8. The prognostic implications of macrophages expressing proliferating cell nuclear antigen in breast cancer depend on immune context. PLoS One. 2013; 8(10):e79114.
    View on PubMed
  9. Variation in centre-specific survival in patients starting renal replacement therapy in England is explained by enhanced comorbidity information from hospitalization data. Nephrol Dial Transplant. 2014 Feb; 29(2):422-30.
    View on PubMed
  10. Biology of breast cancer in Nigerian women: a pilot study. Ann Afr Med. 2012 Jul-Sep; 11(3):169-75.
    View on PubMed
  11. Elevated levels of proliferating and recently migrated tumor-associated macrophages confer increased aggressiveness and worse outcomes in breast cancer. Ann Surg Oncol. 2012 Nov; 19(12):3979-86.
    View on PubMed
  12. Elevated PCNA+ tumor-associated macrophages in breast cancer are associated with early recurrence and non-Caucasian ethnicity. Breast Cancer Res Treat. 2011 Nov; 130(2):635-44.
    View on PubMed
  13. Tumor-associated macrophages in breast cancer as potential biomarkers for new treatments and diagnostics. Expert Rev Mol Diagn. 2011 Jan; 11(1):91-100.
    View on PubMed
  14. Proliferating macrophages associated with high grade, hormone receptor negative breast cancer and poor clinical outcome. Breast Cancer Res Treat. 2011 Aug; 128(3):703-11.
    View on PubMed
  15. Fluvastatin reduces proliferation and increases apoptosis in women with high grade breast cancer. Breast Cancer Res Treat. 2010 Jan; 119(1):137-44.
    View on PubMed
  16. Inhibitory effects of nordihydroguaiaretic acid (NDGA) on the IGF-1 receptor and androgen dependent growth of LAPC-4 prostate cancer cells. Prostate. 2008 Aug 1; 68(11):1232-40.
    View on PubMed
  17. Nordihydroguaiaretic acid (NDGA), an inhibitor of the HER2 and IGF-1 receptor tyrosine kinases, blocks the growth of HER2-overexpressing human breast cancer cells. J Cell Biochem. 2008 Feb 1; 103(2):624-35.
    View on PubMed
  18. Breast cancer growth prevention by statins. Cancer Res. 2006 Sep 1; 66(17):8707-14.
    View on PubMed
  19. Challenge with mammary tumor cells expressing MHC class II and CD80 prevents the development of spontaneously arising tumors in MMTV-neu transgenic mice. Cancer Gene Ther. 2006 Nov; 13(11):1002-10.
    View on PubMed
  20. Language ability after early detection of permanent childhood hearing impairment. N Engl J Med. 2006 May 18; 354(20):2131-41.
    View on PubMed

Go to UCSF Profiles, powered by CTSI